Novel risk loci for COVID-19 hospitalization among admixed American populations

Silvia Diz-de Almeida,[1,2,13,7] Raquel Cruz,[1,2,13,7] Andre D. Luchessi,[3] José M. Lorenzo-Salazar,[4] Miguel López de Heredia,[2] Inés Quintela,[5] Rafaela González-Montelongo,[4] Vivian N. Silbiger,[3] Marta Sevilla Porras,[2,6] Jair Antonio Tenorio Castaño,[2,6,7] Julian Nevado,[2,6,7] Jose María Aguado,[8,9,10,11] Carlos Aguilar,[12] Sergio Aguilera-Albesa,[13,14] Virginia Almadana,[15] Berta Almoguera,[16,2] Nuria Alvarez,[17] Álvaro Andreu-Bernabeu,[18,10] Eunate Arana-Arri,[19,20] Celso Arango,[18,21,10] María J. Arranz,[22] Maria-Jesus Artiga,[23] Raúl C. Baptista-Rosas,[24,25,26] María Barreda- Sánchez,[27,28] Moncef Belhassen-Garcia,[29,30] Joao F. Bezerra,[31] Marcos A.C. Bezerra,[32] Lucía Boix-Palop,[33] María Brion,[34,35] Ramón Brugada,[36,37,35,38] Matilde Bustos,[39] Enrique J. Calderón,[39,40,41] Cristina Carbonell,[42,30] Luis Castano,[19,43,2,44,45] Jose E. Castelao,[46] Rosa Conde-Vicente,[47] M. Lourdes Cordero-Lorenzana,[48] Jose L. Cortes-Sanchez,[49,50,] Marta Corton,[16,2] M. Teresa Darnaude,[51] Alba De Martino-Rodríguez,[52,53] Victor del Campo-Pérez,[54] Aranzazu Diaz de Bustamante,[51] Elena Domínguez-Garrido,[55] Rocío Eirós,[56] María Carmen Fariñas,[57,58,59] María J. Fernandez-Nestosa [60] Uxía Fernández-Robelo,[61] Amanda Fernández-Rodríguez,[62,11] Tania Fernández-Villa,[63,41] Manuela Gago-Domínguez,[5,64] Belén Gil-Fournier,[65] Javier Gómez-Arrue,[52,53] Beatriz González Álvarez,[52,53] Fernan Gonzalez Bernaldo de Quirós,[66] Anna González-Neira,[17] Javier González-Peñas,[18,10,21] Juan F. Gutiérrez-Bautista,[67] María José Herrero,[68,69]Antonio Herrero-Gonzalez,[70] María A. Jimenez-Sousa,[62,11] María Claudia Lattig,[71,72] Anabel Liger Borja,[73] Rosario Lopez-Rodriguez,[16,2,74] Esther Mancebo,[75,76] Caridad Martín-López,[73] Vicente Martín,[63 41] Oscar Martinez-Nieto,[77,72] Iciar Martinez-Lopez,[78,79] Michel F. Martinez-Resendez,[49] Ángel Martinez-Perez,[80] Juliana F. Mazzeu,[81,82,83] Eleuterio Merayo Macías,[84] Pablo Minguez,[16,2] Victor Moreno Cuerda,[85,86] Silviene F. Oliveira,[87,88,83,89] Eva Ortega-Paino,[23] Mara Parellada,[18,21,10] Estela Paz-Artal,[75,76,90] Ney P.C. Santos,[91] Patricia Pérez-Matute,[92] Patricia Perez,[93] M. Elena Pérez-Tomás,[27] Teresa Perucho,[94] Mel·lina Pinsach-Abuin,[36,35] Guillermo Pita,[17] Ericka N. Pompa-Mera,[95,96] Gloria L. Porras-Hurtado,[97] Aurora

eoni
Pujol,[98,2,99] Soraya Ramiro León,[65] Salvador Resino,[62,11] Marianne R. Fernandes,[91,100] Emilio Rodríguez-Ruiz,[101,64] Fernando Rodriguez-Artalejo,[102,103,41,104] José A. Rodriguez-Garcia,[105] Francisco Ruiz-Cabello,[67,106,107] Javier Ruiz-Hornillos,[108,109,110] Pablo Ryan,[111,112,113,11] José Manuel Soria,[80] Juan Carlos Souto,[114] Eduardo Tamayo,[115,116,11] Alvaro Tamayo-Velasco,[117] Juan Carlos Taracido-Fernandez,[70] Alejandro Teper,[118] Lilian Torres-Tobar,[119] Miguel Urioste,[120] Juan Valencia-Ramos,[121] Zuleima Yáñez,[122] Ruth Zarate,[123] Itziar de Rojas,[124,125] Agustín Ruiz,[124,125] Pascual Sánchez,[126] Luis Miguel Real,[127] SCOURGE Cohort Group, Encarna Guillen-Navarro,[27,128,129,130] Carmen Ayuso,[16,2] Esteban Parra,[131] José A. Riancho,[57,58,59,2] Augusto Rojas-Martinez,[132] Carlos Flores,[4,133,134,135,136,*] Pablo Lapunzina,[2,6,7,136] Ángel Carracedo,[1,2,5,64,136,**]

Affiliations

[1], Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain

[2], CIBERER, ISCIII, Madrid, Spain

[3], Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e Toxicologicas, Natal, Brazil

[4], Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife, Spain

[5], Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS) Santiago de Compostela, Spain

[6], Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-IDIPAZ, Madrid, Spain

[7], ERN-ITHACA-European Reference Network

[8], Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

[9], Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de Salud Carlos III, Madrid, Spain

[10], School of Medicine, Universidad Complutense, Madrid, Spain

[11], CIBERINFEC, ISCIII, Madrid, Spain

[12], Hospital General Santa Bárbara de Soria, Soria, Spain

[13], Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,

Pamplona, Spain

[14], Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain

[15], Hospital Universitario Virgen Macarena, Neumología, Seville, Spain

[16], Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez

Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain

[17], Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain

[18], Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,

Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain

[19], Biocruces Bizkai HRI, Bizkaia, Spain

[20], Cruces University Hospital, Osakidetza, Bizkaia, Spain

[21], Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud

Carlos III, Madrid, Spain

[22], Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain

[23], Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain

[24], Hospital General de Occidente, Zapopan Jalisco, Mexico

[25], Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá Jalisco, Mexico

[26], Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá

Jalisco, Mexico

[27], Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain

[28], Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain

[29], Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de

Enfermedades Infecciosas, Salamanca, Spain

[30], Universidad de Salamanca, Salamanca, Spain

[31], Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Brazil

[32], Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil

[33], Hospital Universitario Mutua Terrassa, Barcelona, Spain

[34], Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de

Compostela, Spain

[35], CIBERCV, ISCIII, Madrid, Spain

[36], Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,

Spain

[37], Medical Science Department, School of Medicine, University of Girona, Girona, Spain

[38], Hospital Josep Trueta, Cardiology Service, Girona, Spain

[39], Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas

(CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain

[40], Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,

Seville, Spain

[41], CIBERESP, ISCIII, Madrid, Spain

[42], Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,

Spain

[43], Osakidetza, Cruces University Hospital, Bizkaia, Spain

[44], Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases

(CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain

[45], University of Pais Vasco, UPV/EHU, Bizkaia, Spain

[46], Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de

Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain

[47], Hospital Universitario Río Hortega, Valladolid, Spain

[48], Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña

(CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain

[49], Tecnológico de Monterrey, Monterrey, Mexico

[50], Otto von Guericke University, Departament of Microgravity and Translational Regenerative

Medicine, Magdeburg, Germany

[51], Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain

[52], Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain

[53], Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain

[54], Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia

de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain

[55], Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain

[56], Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain

[57], IDIVAL, Cantabria, Spain

[58], Universidad de Cantabria, Cantabria, Spain

[59], Hospital U M Valdecilla, Cantabria, Spain

[60], Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay

[61], Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),

Sistema Galego de Saúde (SERGAS), A Coruña, Spain

[62], Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto

de Salud Carlos III (ISCIII), Madrid, Spain

[63], Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) - Instituto de

Biomedicina (IBIOMED), Universidad de León, León, Spain

[64], IDIS

[65], Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain

[66], Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina

[67], Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,

Granada, Spain

[68], IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain

[69], Universidad de Valencia, Departamento de Farmacología, Valencia, Spain

[70], Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz

University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain

[71], Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia

[72], SIGEN Alianza Universidad de los Andes - Fundación Santa Fe de Bogotá, Bogotá,

Colombia

[73], Hospital General de Segovia, Medicina Intensiva, Segovia, Spain

[74], Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización

Montepríncipe, 28660 Boadilla del Monte, España

[75], Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain

[76], Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant

Immunology and Immunodeficiencies Group, Madrid, Spain

[77], Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios, Bogotá, Colombia

[78], Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain

[79], Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,

Islas Baleares, Spain

[80], Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant

Pau, IIB Sant Pau, Barcelona, Spain

[81], Universidade de Brasília, Faculdade de Medicina, Brazil

[82], Programa de Pós-Graduação em Ciências Médicas (UnB), Brazil

[83], Programa de Pós-Graduação em Ciencias da Saude (UnB), Brazil

[84], Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain

[85], Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain

[86], Universidad Francisco de Vitoria, Madrid, Spain

[87], Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de

Brasília, Brazil

[88], Programa de Pós-Graduação em Biologia Animal (UnB), Brazil

[89], Programa de Pós-Graduação Profissional em Ensino de Biologia (UnB), Brazil

[90], Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT,

Madrid, Spain

[91], Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil

[92], Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for

Biomedical Research of La Rioja (CIBIR), Logroño, Spain

[93], Inditex, A Coruña, Spain

[94], GENYCA, Madrid, Spain

[95], Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad

de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico

[96], Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional La Raza. Hospital de

Infectología, Mexico City, Mexico

[97], Clinica Comfamiliar Risaralda, Pereira, Colombia

[98], Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,

L'Hospitalet de Llobregat, Spain

[99], Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain

[100], Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil

[101], Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),

Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain

[102], Department of Preventive Medicine and Public Health, School of Medicine, Universidad

Autónoma de Madrid, Madrid, Spain

[103], IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain

[104], IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain

[105], Complejo Asistencial Universitario de León, León, Spain

[106], Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain

[107], Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,

Granada, Spain

[108], Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain

[109], Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -

Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain

[110], Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain

[111], Hospital Universitario Infanta Leonor, Madrid, Spain

[112], Complutense University of Madrid, Madrid, Spain

[113], Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain

[114], Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,

Barcelona, Spain

[115], Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación,

Valladolid, Spain

[116], Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain

[117], Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia,

Valladolid, Spain

[118], Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina

[119], Fundación Universitaria de Ciencias de la Salud

[120], Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain

[121], University Hospital of Burgos, Burgos, Spain

[122], Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia

[123], Centro para el Desarrollo de la Investigación Científica, Paraguay

[124], Research Center and Memory clinic, ACE Alzheimer Center Barcelona, Universitat

Internacional de Catalunya, Spain

[125], Centre for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED),

Instituto de Salud Carlos III, Madrid, Spain

[126], CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain

[127], Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas y

Microbiología, Sevilla, Spain

[128], Sección Genética Médica - Servicio de Pediatría, Hospital Clínico Universitario Virgen de la

Arrixaca, Servicio Murciano de Salud, Murcia, Spain

[129], Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,

Universidad de Murcia (UMU), Murcia, Spain

[130], Grupo Clínico Vinculado, Centre for Biomedical Network Research on Rare Diseases

(CIBERER), Instituto de Salud Carlos III, Madrid, Spain

[131] Department of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario,

Canada.

[132], Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico

[133], Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de

Investigación Sanitaria de Canarias, Santa Cruz de Tenerife, Spain

[134], Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de

Salud Carlos III, Madrid, Spain

[135], Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran

Canaria, Spain

[136], These authors contributed equally: Carlos Flores, Pablo Lapunzina, Ángel Carracedo

[137], These authors contributed equally: Silvia Diz-de Almeida, Raquel Cruz

*Correspondence:

**Correspondence: angel.carracedo@usc.es

Abstract

The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic

risk factors shared between populations have been identified. However, reduced sample

sizes from non-European groups have limited the discovery of population-specific

common risk loci. In this second study nested in the SCOURGE consortium, we

conducted a GWAS for COVID-19 hospitalization in admixed Americans, comprising a

total of 4,702 hospitalized cases recruited by SCOURGE and seven other participating

studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide

significant associations, two of which constitute novel loci and were first discovered in

Latin American populations (*BAZ2B* and *DDIAS*). A trans-ethnic meta-analysis revealed

another novel cross-population risk locus in *CREBBP*. Finally, we assessed the

performance of a cross-ancestry polygenic risk score in the SCOURGE admixed

American cohort. This study constitutes the largest GWAS for COVID-19

hospitalization in admixed Latin Americans conducted to date. This allowed to reveal

novel risk loci and emphasize the need of considering the diversity of populations in

genomic research.

Introduction

To date, more than 50 loci associated with COVID-19 susceptibility, hospitalization,

and severity have been identified using genome-wide association studies (GWAS)[1,2].

The COVID-19 Host Genetics Initiative (HGI) has made significant efforts[3] to augment

the power to identify disease loci by recruiting individuals from diverse populations and

conducting a trans-ancestry meta-analysis. Despite this, the lack of genetic diversity and

a focus on cases of European ancestries still predominate in the studies[4,5]. In addition,

while trans-ancestry meta-analyses are a powerful approach for discovering shared

genetic risk variants with similar effects across populations[6], they may fail to identify

risk variants that have larger effects on particular underrepresented populations. Genetic

disease risk has been shaped by the particular evolutionary history of populations and

environmental exposures[7]. Their action is particularly important for infectious diseases

due to the selective constraints that are imposed by host☐pathogen interactions[8,9].

Literature examples of this in COVID-19 severity include a *DOCK2* gene variant in

East Asians[10] and frequent loss-of-function variants in *IFNAR1* and *IFNAR2* genes in

Polynesian and Inuit populations, respectively[11,12].

Including diverse populations in case☐control GWAS studies with unrelated

participants usually requires a prior classification of individuals in genetically

homogeneous groups, which are typically analyzed separately to control the population

stratification effects[13]. Populations with recent admixture impose an additional

challenge to GWASs due to their complex genetic diversity and linkage disequilibrium (LD) patterns, requiring the development of alternative approaches and a careful inspection of results to reduce false positives due to population structure[7]. In fact, there are benefits in study power from modeling the admixed ancestries either locally, at the regional scale in the chromosomes, or globally, across the genome, depending on factors such as the heterogeneity of the risk variant in frequencies or the effects among the ancestry strata[14]. Despite the development of novel methods specifically tailored for the analysis of admixed populations[15], the lack of a standardized analysis framework and the difficulties in confidently clustering admixed individuals into particular genetic groups often leads to their exclusion from GWAS.

The Spanish Coalition to Unlock Research on Host Genetics on COVID-19 (SCOURGE) recruited COVID-19 patients between March and December 2020 from hospitals across Spain and from March 2020 to July 2021 in Latin America (https://www.scourge-covid.org). A first GWAS of COVID-19 severity among Spanish patients of European descent revealed novel disease loci and explored age- and sex-varying effects of genetic factors[16]. Here, we present the findings of a GWAS meta-analysis in admixed Latin American (AMR) populations, comprising individuals from the SCOURGE Latin-American cohort and the HGI studies, which allowed us to identify two novel severe COVID-19 loci, *BAZ2B* and *DDIAS*. Further analyses modeling the admixture from three genetic ancestral components and performing a trans-ethnic meta-analysis led to the identification of an additional risk locus near *CREBBP*. We finally assessed a cross-ancestry polygenic risk score model with variants associated with critical COVID-19.

Results

Meta-analysis of COVID-19 hospitalization in admixed Americans

 Study cohorts

Within the SCOURGE consortium, we included 1,608 hospitalized cases and 1,887

controls (not hospitalized COVID-19 patients) from Latin American countries and from

recruitments of individuals of Latin American descent conducted in Spain

(Supplementary Table 1). Quality control details and estimation of global genetic

inferred ancestry (GIA) (Supplementary Figure 1) are described in Methods, whereas

clinical and demographic characteristics of patients included in the analysis are shown

in Table 1. Summary statistics from the SCOURGE cohort were obtained under a

logistic mixed model with the SAIGE model (Methods). Another seven studies

participating in the COVID-19 HGI consortium were included in the meta-analysis of

COVID-19 hospitalization in admixed Americans (Figure 1).

GWAS meta-analysis

We performed a fixed-effects GWAS meta-analysis using the inverse of the variance as

weights for the overlapping markers. The combined GWAS sample size consisted of

4,702 admixed AMR hospitalized cases and 68,573 controls.

This GWAS meta-analysis revealed genome-wide significant associations at four risk

loci (Table 2, Figure 2), two of which (*BAZ2B* and *DDIAS*) were novel discoveries.

Four lead variants were identified, linked to other 310 variants (Supplementary Tables

2-3). A gene-based association test revealed a significant association in *BAZ2B* and in

previously known COVID-19 risk loci: *LZTFL1*, *XCR1*, *FYCO1*, *CCR9*, and *IFNAR2*

(Supplementary Table 4).

Located within the *BAZ2B* gene, the sentinel variant rs13003835 is an intronic variant

associated with an increased risk of COVID-19 hospitalization (Odds Ratio [OR]=1.20,

95% Confidence Interval [CI]=1.12-1.27, p=3.66x10^{-8}). This association was not

previously reported in any GWAS of COVID-19 published to date. Interestingly,

rs13003835 did not reach significance (p=0.972) in the COVID-19 HGI trans-ancestry

meta-analysis including the five population groups[1].

The other novel risk locus is led by the sentinel variant rs77599934, a rare intronic

variant located in chromosome 11 within *DDIAS* and associated with the risk of

COVID-19 hospitalization (OR=2.27, 95% CI=1.70-3.04, p=2.26x10^{-8}).

We also observed a suggestive association with rs2601183 in chromosome 15, which is

located between *ZNF774* and *IQGAP1* (allele-G OR=1.20, 95% CI=1.12-1.29,

p=6.11x10^{-8}, see Supplementary Table 2), which has not yet been reported in any other

GWAS of COVID-19 to date.

The GWAS meta-analysis also pinpointed two significant variants at known loci,

LZTFL1 and *FOXP4*. The SNP rs35731912 was previously associated with COVID-19

severity in EUR populations[17], and it was mapped to *LZTFL1*. While rs2477820 is a

novel risk variant within the *FOXP4 gene*, it has a moderate LD (r^2=0.295) with

rs2496644, which has been linked to COVID-19 hospitalization[18]. This is consistent

with the effects of LD in tag-SNPs when conducting GWAS in diverse populations.

None of the lead variants was associated with the comorbidities included in Table 1.

Functional mapping of novel risk variants

Variants belonging to the lead loci were prioritized by positional and expression

quantitative trait loci (eQTL) mapping with FUMA, resulting in 31 mapped genes

(Supplementary Table 5). Within the region surrounding the lead variant in

chromosome 2, FUMA prioritized four genes in addition to *BAZ2B* (*PLA2R1*, *LY75*,

WDSUB1, and *CD302*). rs13003835 (allele C) is an eQTL of *LY75* in the esophagus

mucosa (NES=0.27) and of *BAZ2B-AS* in whole blood (NES=0.27), while rs2884110

(R^2=0.85) is an eQTL of *LY75* in lung (NES=0.22). As for the chromosome 11,

rs77599934 (allele G) is in moderate-to-strong LD (r^2=0.776) with rs60606421 (G

deletion, allele -) which is an eQTL associated with a reduced expression of *DDIAS* in

the lungs (NES=-0.49, allele -). Associations with expression are shown in the

supplementary Figure 4. The sentinel variant for the region in chromosome 16 is in

perfect LD (r^2=1) with rs601183, an eQTL of *ZNF774* in the lung.

Bayesian fine mapping

We performed different approaches to narrow down the prioritized loci to a set of most

likely genes driving the associations. First, we computed credible sets at the 95%

confidence level for causal variants and annotated them with VEP (and V2G aggregate

scoring. The 95% confidence credible set from the region of chromosome 2 around

rs13003835 included 76 variants, which can be found in the Supplementary Table 6

(VEP and V2G annotations are included in the Supplementary Tables 7 and 8). TheV2G

score prioritized *BAZ2B* as the most likely gene driving the association. However, the

approach was unable to converge allocating variants in a 95% confidence credible set

for the region in chromosome 11.

Transcriptome-wide association study (TWAS)

Five novel genes, namely, *SLC25A37*, *SMARCC1*, *CAMP*, *TYW3*, and *S100A12*

(supplementary Table 9), were found to be significantly associated in the cross-tissue

TWAS. To our knowledge, these genes have not been reported previously in any

COVID-19 TWAS or GWAS analyses published to date. In the single tissue analyses,

ATP5O and *CXCR6* were significantly associated in the lungs, *CCR9* was significantly

associated in whole blood, and *IFNAR2* and *SLC25A37* were associated in lymphocytes.

Likewise, we carried out TWAS analyses using the models trained in the admixed

populations. However, no significant gene pairs were detected in this case. The top 10

genes with the lowest p-values for each of the datasets (Puerto-Ricans, Mexicans,

African-Americans and pooled cohorts) are shown in the Supplementary Table 10.

Although not significant, *KCNC3* was repeated in the four analyses, whereas

MAPKAPK3, *NAPSA* and *THAP5* were repeated in 3 out of 4. Both *NAPSA* and *KCNC3*

are located in the chromosome 19 and were reported in the latest HGI meta-analysis[19].

All mapped genes from analyses conducted in AMR populations are shown in Figure 5.

Genetic architecture of COVID-19 hospitalization in AMR populations

Allele frequencies of rs13003835 and rs77599934 across ancestries

Neither rs13003835 (*BAZ2B*) nor rs77599934 (*DDIAS*) were significantly associated in

the COVID-19 HGI B2 cross-population or population-specific meta-analyses. Thus,

we investigated their allele frequencies (AF) across populations and compared their

effect sizes.

According to gnomAD v3.1.2, the T allele at rs13003835 (*BAZ2B*) has an AF of 43% in

admixed AMR groups, while AF is lower in the EUR populations (16%) and in the

global sample (29%). Local ancestry inference (LAI) reported by gnomAD shows that

within the Native-American component, the risk allele T is the major allele, whereas it

is the minor allele within the African and European LAI components. These large

differences in AF might be the reason underlying the association found in AMR

populations. However, when comparing effect sizes between populations, we found that

they were in opposite directions between SAS-AMR and EUR-AFR-EAS and that there

was large heterogeneity among them (Figure 3). We queried SNPs within 50kb

windows of the lead variant in each of the other populations that had p-value<0.01. The

variant with the lowest p-value in the EUR population was rs559179177 (p=1.72×10^{-4}),

which is in perfect LD (r^2=1) in the 1KGP EUR population with our sentinel variant

(rs13003835), and in moderate LD r^2=0.4 in AMR populations. Since this variant was

absent from the AMR analysis, probably due to its low frequency, it could not be meta-

analyzed. Power calculations revealed that the EUR analysis was underpowered for this

variant to achieve genome-wide significance (77.6%, assuming an effect size of 0.46,

EAF= 0.0027, and number of cases/controls as shown in the HGI website for B2-EUR).

In the cross-population meta-analysis (B2-ALL), rs559179177 obtained a p-value of

5.9×10^{-4}.

rs77599934 (*DDIAS*) had an AF of 1.1% for the G allele in the nonhospitalized

controls (Table 2), in line with the recorded gnomAD AF of 1% in admixed AMR

groups. This variant has the potential to be a population-specific variant, given the allele

frequencies in other population groups, such as EUR (0% in Finnish, 0.025% in non-

Finnish), EAS (0%) and SAS (0.042%), and its greater effect size over AFR populations

(Figure 3). Examining the LAI, the G allele occurs at a 10.8% frequency in the African

component, while it is almost absent in the Native-American and European. Due to its

low MAF, rs77599934 was not analyzed in the COVID-19 HGI B2 cross-population

meta-analysis and was only present in the HGI B2 AFR population-specific meta-

analysis, precluding the comparison (Figure 3). For this reason, we retrieved the variant

with the lowest p-value within a 50 kb region around rs77599934 in the COVID-19

HGI cross-population analysis to investigate whether it was in moderate-to-strong LD

with our sentinel variant. The variant with the smallest p-value was rs75684040

(OR=1.07, 95% CI=1.03-1.12, p=1.84×10^{-3}). However, LD calculations using the 1KGP

phase 3 dataset indicated that rs77599934 and rs75684040 were poorly correlated

(r^2=0.11). As for AFR populations, the variant with the lowest p-value was rs138860115

(p=8.3x10^{-3}), but it was not correlated with the lead SNP of this locus.

Cross-population meta-analyses

We carried out two cross-ancestry inverse variance-weighted fixed-effects meta-

analyses with the admixed AMR GWAS meta-analysis results to evaluate whether the

discovered risk loci replicated when considering other population groups. In doing so,

we also identified novel cross-population COVID-19 hospitalization risk loci.

First, we combined the SCOURGE Latin American GWAS results with the HGI B2

ALL analysis (supplementary Table 11). We refer to this analysis as the SC-HGI$_{ALL}$

meta-analysis. Out of the 40 genome-wide significant loci associated with COVID-19

hospitalization in the last HGI release[1], this study replicated 39, and the association was

stronger than in the original study in 29 of those (supplementary Table 12). However,

the variant rs13003835 located in *BAZ2B* did not replicate (OR=1.00, 95% CI=0.98-

1.03, p=0.644).

In this cross-ancestry meta-analysis, we replicated two associations that were not found

in HGIv7, albeit they were sentinel variants in the latest GenOMICC meta-analysis[2].

We found an association at the *CASC20* locus led by the variant rs2876034 (OR=0.95,

95% CI=0.93-0.97, p=2.83x10^{-8}). This variant is in strong LD with the sentinel variant

of that study (rs2326788, r^2=0.92), which was associated with critical COVID-19[2]. In

addition, this meta-analysis identified the variant rs66833742 near *ZBTB7A* associated

with COVID-19 hospitalization (OR=0.94, 95% CI=0.92-0.96, p=2.50x10^{-8}). Notably,

rs66833742 or its perfect proxy rs67602344 (r^2=1) are also associated with upregulation

of *ZBTB7A* in whole blood and in esophageal mucosa. This variant was previously

associated with COVID-19 hospitalization[2].

In a second analysis, we also explored the associations across the defined admixed

AMR, EUR, and AFR ancestral sources by combining through meta-analysis the

SCOURGE Latin American GWAS results with the HGI studies in EUR, AFR, and

admixed AMR and excluding those from EAS and SAS (supplementary Table 13). We

refer to this as the SC-HGI$_{3POP}$ meta-analysis. The association at rs13003835 (*BAZ2B*,

OR=1.01, 95% CI=0.98-1.03, p=0.605) was not replicated, and rs77599934 near *DDIAS*

could not be assessed, although the association at the *ZBTB7A* locus was confirmed

(rs66833742, OR=0.94, 95% CI=0.92-0.96, p=1.89×10^{-8}). The variant rs76564172

located near *CREBBP* also reached statistical significance (OR=1.31, 95% CI=1.25-

1.38, p=9.64×10^{-9}). The sentinel variant of the region linked to *CREBBP* (in the trans-

ancestry meta-analysis) was also subjected a Bayesian fine mapping (supplementary

Table 6). Eight variants were included in the credible set for the region in chromosome

16 (meta-analysis SC-HGI$_{3POP}$).

453   Polygenic risk score models

Using the 49 variants associated with disease severity that are shared across populations

according to the HGIv7, we constructed a polygenic risk score (PGS) model to assess its

generalizability in the admixed AMR (supplementary Table 14). First, we calculated the

PGS for the SCOURGE Latin Americans and explored the association with COVID-19

hospitalization under a logistic regression model. The PGS model was associated with a

1.48-fold increase in COVID-19 hospitalization risk per every PGS standard deviation.

It also contributed to explaining a slightly larger variance ($\Delta R2=1.07\%$) than the

baseline model.

Subsequently, we divided the individuals into PGS deciles and percentiles to assess

their risk stratification. The median percentile among controls was 40, while in cases, it

was 63. Those in the top PGS decile exhibited a 2.89-fold (95% CI=2.37-3.54,

p=$1.29x10^{-7}$) greater risk compared to individuals in the deciles between 4 and 6

(corresponding to a score of the median distribution).

We also examined the distribution of PGS scores across a 5-level severity scale to

further determine if there was any correspondence between clinical severity and genetic

risk. Median PGS scores were lower in the asymptomatic and mild groups, whereas

higher median scores were observed in the moderate, severe, and critical patients

(Figure 4). We fitted a multinomial model using the asymptomatic class as a reference

and calculated the OR for each category (supplementary Table 15), observing that the

disease genetic risk was similar among asymptomatic, mild, and moderate patients.

Given that the PGS was built with variants associated with critical disease and/or

hospitalization and that the categories severe and critical correspond to hospitalized

patients, these results underscore the ability of cross-ancestry PGS for risk stratification

even in an admixed population.

DISCUSSION

We have conducted the largest GWAS meta-analysis of COVID-19 hospitalization in

admixed AMR to date. While the genetic risk basis discovered for COVID-19 is largely

shared among populations, trans-ancestry meta-analyses on this disease have primarily

included EUR samples. This dominance of GWAS in Europeans and the subsequent

bias in sample sizes can mask population-specific genetic risks (i.e., variants that are

monomorphic in some populations) or be less powered to detect risk variants having

higher allele frequencies in population groups other than Europeans. In this sense, after

combining data from admixed AMR patients, we found two risk loci that were first

discovered in a GWAS of Latin American populations. Interestingly, the sentinel

variant rs77599934 in the *DDIAS* gene is a rare coding variant (~1% for allele G) with a

large effect on COVID-19 hospitalization that is nearly monomorphic in most of the

other populations. This has likely led to its exclusion from the cross-population meta-

analyses conducted to date, remaining undetectable.

Fine mapping of the region harboring *DDIAS* did not reveal further information about

which gene could be the more prone to be causal or about the functional consequences

of the risk variant, but our sentinel variant was in strong LD with an eQTL that

associated with reduced gene expression of *DDIAS* in the lung. *DDIAS,* known as

damage-induced apoptosis suppressor gene, is itself a plausible candidate gene. It has

been linked to DNA damage repair mechanisms: research has shown that depletion of

DDIAS leads to an increase in ATM phosphorylation and the formation of p53-binding

protein (53BP1) foci, a known biomarker of DNA double-strand breaks, suggesting a

potential role in double-strand break repair[20]. Interestingly, a study found that infection

by SARS-CoV-2 also triggered the phosphorylation of ATM kinase and inhibited repair

mechanisms, causing the accumulation of DNA damage[21]. This gene has also been

proposed as a potential biomarker for lung cancer after finding that it interacts with

STAT3 in lung cancer cells, regulating IL-6[22,23] and thus mediating inflammatory

processes, while another study determined that its blockade inhibited lung cancer cell

growth[24].Another prioritized gene from this region was *PRCP*, an angiotensinase which

shares substrate specificity with ACE2 receptor. It has been positively linked to

hypertension and some studies have raised hypotheses on its role in COVID-19

progression, particularly in relation to the development of pro-thrombotic events [25,26].

The risk region found in chromosome 2 harbors more than one gene. The lead variant rs13003835 is located within *BAZ2B*, and it increases the expression of the antisense *BAZ2B* gene in whole blood. *BAZ2B* encodes one of the regulatory subunits of the Imitation switch (ISWI) chromatin remodelers[27] constituting the BRF-1/BRF-5 complexes with SMARCA1 and SMARCA5, respectively. Interestingly, it was discovered that *lnc-BAZ2B* promotes macrophage activation through regulation of *BAZ2B* expression. Its over-expression resulted in pulmonary inflammation and elevated levels of *MUC5AC* in mice with asthma[28]. This variant was also an eQTL for *LY75* (encoding lymphocyte antigen 75) in the esophageal mucosa tissue. Lymphocyte antigen 75 is involved in immune processes through antigen presentation in dendritic cells and endocytosis[29] and has been associated with inflammatory diseases, representing a compelling candidate for the region. Increased expression of *LY75* has been detected within hours after infection by SARS-CoV-2[30,31]. It is worth noting that differences in AF for this variant suggest that analyses in AMR populations might be more powered to detect the association, supporting the necessity of population-specific studies.

A third novel risk region was observed on chromosome 15 between the *IQGAP1* and *ZNF774 genes*, although it did not reach genome-wide significance.

Secondary analyses revealed five TWAS-associated genes, some of which have already been linked to severe COVID-19. In a comprehensive multitissue gene expression profiling study[32], decreased expression of *CAMP* and *S100A8/S100A9* genes in patients with severe COVID-19 was observed, while another study detected the upregulation of *SCL25A37* among patients with severe COVID-19[33]. *SMARCC1* is a subunit of the SWI/SNF chromatin remodeling complex that has been identified as proviral for SARS-CoV-2 and other coronavirus strains through a genome-wide screen[34]. This complex is

crucial for *ACE2* expression and viral entry into the cell[35]. However, it should be noted

that using eQTL mostly from European populations such as those in GTEx could result

in reduced power to detect associations.

To explore the genetic architecture of the trait among admixed AMR populations, we

performed two cross-ancestry meta-analyses including the SCOURGE Latin American

cohort GWAS findings. We found that the two novel risk variants were not associated

with COVID-19 hospitalization outside the population-specific meta-analysis,

highlighting the importance of complementing trans-ancestry meta-analyses with group-

specific analyses. Notably, this analysis did not replicate the association at the *DSTYK*

locus, which was associated with severe COVID-19 in Brazilian individuals with higher

European admixture[36]. This lack of replication aligns with the initial hypothesis of that

study suggesting that the risk haplotype was derived from European populations, as we

reduced the weight of this ancestral contribution in our study by excluding those

individuals.

Moreover, these cross-ancestry meta-analyses pointed to three loci that were not

genome-wide significant in the HGIv7 ALL meta-analysis: a novel locus at *CREBBP*

and two loci at *ZBTB7A* and *CASC20* that were reported in another meta-analysis.

CREBBP and *ZBTB7A* achieved a stronger significance when considering only the

EUR, AFR, and admixed AMR GIA groups. According to a recent study, elevated

levels of the *ZBTB7A* gene promote a quasihomeostatic state between coronaviruses and

host cells, preventing cell death by regulating oxidative stress pathways[37]. This gene is

involved in several signaling pathways, such as B and T-cell differentiation[38]. On a

separate note, *CREBBP* encodes the CREB binding protein (CBP), which is involved in

transcriptional activation and is known to positively regulate the type I interferon

response through virus-induced phosphorylation of IRF-3[39]. In addition, the

CREBP/CBP interaction has been implicated in SARS-CoV-2 infection[40] via the cAMP/PKA pathway. In fact, cells with suppressed *CREBBP* gene expression exhibit reduced replication of the so-called Delta and Omicron SARS-CoV-2 variants[40].

We developed a cross-population PGS model, which effectively stratified individuals based on their genetic risk and demonstrated consistency with the clinical severity classification of the patients. Only a few polygenic scores were derived from COVID-19 GWAS data. Horowitz et al. (2022)[41] developed a score using 6 and 12 associated variants (PGS ID: PGP000302) and reported an associated OR (top 10% vs rest) of 1.38 for risk of hospitalization in European populations, whereas the OR for Latin-American populations was 1.56. Since their sample size and the number of variants included in the PGS were lower, direct comparisons are not straightforward. Nevertheless, our analysis provides the first results for a PRS applied to a relatively large AMR cohort, being of value for future analyses regarding PRS transferability.

This study is subject to limitations, mostly concerning sample recruitment and composition. The SCOURGE Latino-American sample size is small, and the GWAS is likely underpowered. Another limitation is the difference in case☐control recruitment across sampling regions that, yet controlled for, may reduce the ability to observe significant associations driven by different compositions of the populations. In this sense, the identified risk loci might not replicate in a cohort lacking any of the parental population sources from the three-way admixture. Likewise, we could not explicitly control for socioenvironmental factors that could have affected COVID-19 spread and hospitalization rates, although genetic principal components are known to capture nongenetic factors. Finally, we must acknowledge the lack of a replication cohort. We used all the available GWAS data for COVID-19 hospitalization in admixed AMR in this meta-analysis due to the low number of studies conducted. Therefore, we had no

studies to replicate or validate the results. These concerns may be addressed in the

future by including more AMR GWAS in the meta-analysis, both by involving diverse

populations in study designs and by supporting research from countries in Latin

America.

This study provides novel insights into the genetic basis of COVID-19 severity,

emphasizing the importance of considering host genetic factors by using non-European

populations, especially of admixed sources. Such complementary efforts can pin down

new variants and increase our knowledge on the host genetic factors of severe COVID-

19.

Materials and methods

GWAS in Latin Americans from SCOURGE

The SCOURGE Latin American cohort

A total of 3,729 COVID-19-positive cases were recruited across five countries from

Latin America (Mexico, Brazil, Colombia, Paraguay, and Ecuador) by 13 participating

centers (supplementary Table 1) from March 2020 to July 2021. In addition, we

included 1,082 COVID-19-positive individuals recruited between March and December

2020 in Spain who either had evidence of origin from a Latin American country or

showed inferred genetic admixture between AMR, EUR, and AFR (with < 0.05%

SAS/EAS). These individuals were excluded from a previous SCOURGE study that

focused on participants with European genetic ancestries[16]. We used hospitalization as a

proxy for disease severity and defined COVID-19-positive patients who underwent

hospitalization as a consequence of the infection as cases and those who did not need

hospitalization due to COVID-19 as controls.

Samples and data were collected with informed consent after the approval of the Ethics

and Scientific Committees from the participating centers and by the Galician Ethics

Committee Ref 2020/197. Recruitment of patients from IMSS (in Mexico, City) was

approved by the National Committee of Clinical Research from Instituto Mexicano del

Seguro Social, Mexico (protocol R-2020-785-082).

Samples and data were processed following normalized procedures. The REDCap

electronic data capture tool[42,43], hosted at Centro de Investigación Biomédica en Red

(CIBER) from the Instituto de Salud Carlos III (ISCIII), was used to collect and manage

demographic, epidemiological, and clinical variables. Subjects were diagnosed with

COVID-19 based on quantitative PCR tests (79.3%) or according to clinical (2.2%) or

laboratory procedures (antibody tests: 16.3%; other microbiological tests: 2.2%).

SNP array genotyping

Genomic DNA was obtained from peripheral blood and isolated using the Chemagic

DNA Blood 100 kit (PerkinElmer Chemagen Technologies GmbH), following the

manufacturer's recommendations.

Samples were genotyped with the Axiom Spain Biobank Array (Thermo Fisher

Scientific) following the manufacturer's instructions in the Santiago de Compostela

Node of the National Genotyping Center (CeGen-ISCIII; http://www.usc.es/cegen).

This array contains probes for genotyping a total of 757,836 SNPs. Clustering and

genotype calling were performed using Axiom Analysis Suite v4.0.3.3 software.

Quality control steps and variant imputation

A quality control (QC) procedure using PLINK 1.9[44] was applied to both samples and

the genotyped SNPs. We excluded variants with a minor allele frequency (MAF) <1%,

a call rate <98%, and markers strongly deviating from Hardy-Weinberg equilibrium

expectations ($p<1\times10^{-6}$) with mid-p adjustment. We also explored the excess of

heterozygosity to discard potential cross-sample contamination. Samples missing >2%

of the variants were filtered out. Subsequently, we kept the autosomal SNPs, removed

high-LD regions and conducted LD pruning (windows of 1,000 SNPs, with a step size

of 80 and a r^2 threshold of 0.1) to assess kinship and estimate the global ancestral

proportions. Kinship was evaluated based on IBD values, removing one individual from

each pair with PI_HAT>0.25 that showed a Z0, Z1, and Z2 coherent pattern (according

to the theoretical expected values for each relatedness level). Genetic principal

components (PCs) were calculated with PLINK with the subset of LD pruned variants.

Genotypes were imputed with the TOPMed version r2 reference panel (GRCh38) using

the TOPMed Imputation Server, and variants with Rsq<0.3 or with MAF<1% were

filtered out. A total of 4,348 individuals and 10,671,028 genetic variants were included

in the analyses.

Genetic admixture estimation

Global genetic inferred ancestry (GIA), referred to the genetic similarity to the used

reference individuals, was estimated with ADMIXTURE[45] v1.3 software following a

two-step procedure. First, we randomly sampled 79 European (EUR) and 79 African

(AFR) samples from The 1000 Genomes Project (1KGP)[46] and merged them with the

79 Native American (AMR) samples from Mao *et al.*[47] keeping the biallelic SNPs. LD-

pruned variants were selected from this merge using the same parameters as in the QC.

We then run an unsupervised analysis with K=3 to redefine and homogenize the clusters

and to compose a refined reference for the analyses by applying a threshold of ≥95% of

belonging to a particular cluster. As a result, 20 AFR, 18 EUR, and 38 AMR individuals

were removed. The same LD-pruned variants data from the remaining individuals were

merged with the SCOURGE Latin American cohort to perform supervised clustering

and estimate admixture proportions. A total of 471 samples from the SCOURGE cohort

with >80% estimated European GIA were removed to reduce the weight of the

European ancestral component, leaving a total of 3,512 admixed Latin American

(AMR) subjects for downstream analyses.

Association analysis

The results for the SCOURGE Latin American GWAS were obtained by testing for

COVID-19 hospitalization as a surrogate of severity. To accommodate the continuum of

GIA in the cohort, we opted for a joint testing of all the individuals as a single study

using a mixed regression model, as this approach has demonstrated a greater power and

sufficient control of population structure[48]. The SCOURGE cohort consisted of 3,512

COVID-19-positive patients: cases (n=1,625) were defined as hospitalized COVID-19

patients, and controls (n=1,887) were defined as nonhospitalized COVID-19-positive

patients.

Logistic mixed regression models were fitted using the SAIGEgds[49] package in R,

which implements the two-step mixed SAIGE[50] model methodology and the SPA test.

Baseline covariables included sex, age (continuous), and the first 10 PCs. To account

for potential heterogeneity in the recruitment and hospitalization criteria across the

participating countries, we adjusted the models by groups of the recruitment areas

classified into six categories: Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain.

This dataset has not been used in any previously published GWAS of COVID-19.

Meta-analysis of Latin American populations

The results of the SCOURGE Latin American cohort were meta-analyzed with the

AMR HGI-B2 data, conforming our primary analysis. Summary results from the HGI

freeze 7 B2 analysis corresponding to the admixed AMR population were obtained from

the public repository (April 8, 2022: https://www.covid19hg.org/results/r7/), summing

up 3,077 cases and 66,686 controls from seven contributing studies. We selected the B2

phenotype definition because it offered more power, and the presence of population

controls not ascertained for COVID-19 does not have a drastic impact on the association

results.

The meta-analysis was performed using an inverse-variance weighting method in

METAL[51]. The average allele frequency was calculated, and variants with low

imputation quality (Rsq<0.3) were filtered out, leaving 10,121,172 variants for meta-

analysis.

Heterogeneity between studies was evaluated with Cochran's Q test. The inflation of

results was assessed based on a genomic control (lambda).

Replicability of associations

The model-based method MAMBA[52] was used to calculate the posterior probabilities

of replication for each of the lead variants. Variants with $p<1 \times 10^{-05}$ were clumped and

combined with random pruned variants from the 1KGP AMR reference panel. Then,

MAMBA was applied to the set of significant and non-significant variants.

Each of the lead variants was also tested for association with the main comorbidities in

the SCOURGE cohort with logistic regression models (adjusted by the same base

covariables as the GWAS).

Definition of the genetic risk loci and putative functional impact

Definition of lead variant and novel loci

To define the lead variants in the loci that were genome-wide significant, LD-clumping

was performed on the meta-analysis data using a threshold p-value$<5\times10^{-8}$, clump

distance=1500 kb, independence set at a threshold r^2=0.1 and the SCOURGE cohort

genotype data as the LD reference panel. Independent loci were deemed as a novel

finding if they met the following criteria: 1) p-value$<5\times10^{-8}$ in the meta-analysis and p-

value$>5\times10^{-8}$ in the HGI B2 ALL meta-analysis or in the HGI B2 AMR and AFR and

EUR analyses when considered separately; 2) Cochran's Q-test for heterogeneity of

effects is $<0.05/N_{loci}$, where N_{loci} is the number of independent variants with $p<5\times10^{-8}$;

and 3) the nearest gene has not been previously described in the latest HGIv7 update.

Annotation and initial mapping

Functional annotation was performed with FUMA[53] for those variants with a p-

value$<5\times10^{-8}$ or in moderate-to-strong LD (r^2>0.6) with the lead variants, where the LD

was calculated from the 1KGP AMR panel. Genetic risk loci were defined by collapsing

LD blocks within 250 kb. Then, genes, scaled CADD v1.4 scores, and RegulomeDB

v1.1 scores were annotated for the resulting variants with ANNOVAR in FUMA[53].

Gene-based analysis was also performed using MAGMA[54] as implemented in FUMA

under the SNP-wide mean model using the 1KGP AMR reference panel. Significance

was set at a threshold $p<2.66\times10^{-6}$ (which assumes that variants can be mapped to a total

of 18,817 genes).

FUMA allowed us to perform initial gene mapping by two approaches: (1) positional

mapping, which assigns variants to genes by physical distance using 10-kb windows;

and (2) eQTL mapping based on GTEx v.8 data from whole blood, lungs, lymphocytes,

and esophageal mucosa tissues, establishing a false discovery rate (FDR) of 0.05 to

declare significance for variant-gene pairs.

Subsequently, to assign the variants to the most likely gene driving the association, we

refined the candidate genes by fine mapping the discovered regions

Bayesian fine-mapping

To conduct a Bayesian fine mapping, credible sets for the genetic loci considered novel

findings were calculated on the results from each of the three meta-analyses to identify a

subset of variants most likely containing the causal variant at the 95% confidence level,

assuming that there is a single causal variant and that it has been tested. We used

corrcoverage (https://cran.rstudio.com/web/packages/corrcoverage/index.html) for R to

calculate the posterior probabilities of the variant being causal for all variants with a

$r^2>0.1$ with the leading SNP and within 1 Mb except for the novel variant in

chromosome 19, for which we used a window of 0.5 Mb. Variants were added to the

credible set until the sum of the posterior probabilities was ≥0.95.

VEP and V2G annotation

We used the Variant-to-Gene (V2G) score to prioritize the genes that were most likely

affected by the functional evidence based on expression quantitative trait loci (eQTL),

chromatin interactions, in silico functional predictions, and distance between the

prioritized variants and transcription start site (TSS), based on data from the Open

Targets Genetics portal[55]. Details of the data integration and the weighting of each of

the datasets are described with detail here: https://genetics-docs.opentargets.org/our-

approach/data-pipeline. V2G is a score for ranking the functional genomics evidence

that supports the connection between variants and genes (the higher the score the more

likely the variant to be functionally implicated on the assigned gene). We used VEP

release 111 (URL: https://www.ensembl.org/info/docs/tools/vep/index.html; accessed

April 10, 2024) [56] to annotate the following: gene symbol, function (exonic, intronic,

intergenic, non-coding RNA, etc.), impact, feature type, feature, and biotype.

We queried the GWAS Catalog (date of accession: 01/07/2024) for evidence of

association of each of the prioritized genes with traits related to lung diseases or

phenotypes. Lastly, those which were linked to COVID-19, infection, or lung diseases

in the revised literature were classified as "literature evidence".

Transcription-wide association studies

Transcriptome-wide association studies (TWAS) were conducted using the pretrained

prediction models with MASHR-computed effect sizes on GTEx v8 datasets[57,58]. The

results from the Latin American meta-analysis were harmonized and integrated with the

prediction models through S-PrediXcan[59] for lung, whole blood, lymphocyte and

esophageal mucosal tissues. Statistical significance was set at p-value<0.05 divided by

the number of genes that were tested for each tissue. Subsequently, we leveraged results

for all 49 tissues and ran a multitissue TWAS to improve the power for association, as

demonstrated recently[60]. TWAS was also performed using recently published gene

expression datasets derived from a cohort of African Americans, Puerto Ricans, and

Mexican Americans (GALA II-SAGE)[61].

Cross-population meta-analyses

We conducted two additional meta-analyses to investigate the ability of combining

populations to replicate our discovered risk loci. This methodology enabled the

comparison of effects and the significance of associations in the novel risk loci between

the results from analyses that included or excluded other population groups.

The first meta-analysis comprised the five populations analyzed within HGI (B2-ALL).

Additionally, to evaluate the three GIA components within the SCOURGE Latin

American cohort[62], we conducted a meta-analysis of the admixed AMR, EUR, and AFR

cohorts (B2). All summary statistics were retrieved from the HGI repository. We

applied the same meta-analysis methodology and filters as in the admixed AMR meta-

analysis.

Cross-population Polygenic Risk Score

A polygenic risk score (PGS) for critical COVID-19 was derived by combining the

variants associated with hospitalization or disease severity that have been discovered to

date. We curated a list of lead variants that were 1) associated with either severe disease

or hospitalization in the latest HGIv7 release[1] (using the hospitalization weights) or 2)

associated with severe disease in the latest GenOMICC meta-analysis[2] that were not

reported in the latest HGI release. A total of 48 markers were used in the PGS model

(see supplementary Table 13) since two variants were absent from our study.

Scores were calculated and normalized for the SCOURGE Latin American cohort with

PLINK 1.9. This cross-ancestry PGS was used as a predictor for hospitalization

(COVID-19-positive patients who were hospitalized *vs.* COVID-19-positive patients

who did not necessitate hospital admission) by fitting a logistic regression model.

Prediction accuracy for the PGS was assessed by performing 500 bootstrap resamples of

the increase in the pseudo-R-squared. We also divided the sample into deciles and

percentiles to assess risk stratification. The models were fit for the dependent variable

adjusting for sex, age, the first 10 PCs, and the sampling region (in the Admixed AMR

cohort) with and without the PGS, and the partial pseudo-R2 was computed and

averaged among the resamples.

A clinical severity scale was used in a multinomial regression model to further evaluate

the power of this cross-ancestry PGS for risk stratification. These severity strata were

defined as follows: 0) asymptomatic; 1) mild, that is, with symptoms, but without

pulmonary infiltrates or need of oxygen therapy; 2) moderate, that is, with pulmonary

infiltrates affecting <50% of the lungs or need of supplemental oxygen therapy; 3)

severe disease, that is, with hospital admission and $PaO_2<65$ mmHg or $SaO_2<90\%$,

$PaO_2/FiO_2<300$, $SaO_2/FiO_2<440$, dyspnea, respiratory frequency$\geq$22 bpm, and

infiltrates affecting >50% of the lungs; and 4) critical disease, that is, with an admission

to the ICU or need of mechanical ventilation (invasive or noninvasive).

Data availability

Summary statistics from the SCOURGE Latin American GWAS and the analysis scripts

are available from the public repository https://github.com/CIBERER/Scourge-

COVID19.

Funding

Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B.,

COV20_00181 to C.A., COV20_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.);

European Union (ERDF) 'A way of making Europe'. Fundación Amancio Ortega,

Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association

(to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación

(RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140

'Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19' to C.F.)

and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57

to C.F.).

SD-DA was supported by a Xunta de Galicia predoctoral fellowship.

Author contributions

Acknowledgments

The contribution of the Centro National de Genotipado (CEGEN) and Centro de

Supercomputación de Galicia (CESGA) for funding this project by providing

supercomputing infrastructures is also acknowledged. The authors are also particularly

grateful for the supply of material and the collaboration of patients, health professionals

from participating centers and biobanks. Namely, Biobanc-Mur, and biobancs of the

Complexo Hospitalario Universitario de A Coruña, Complexo Hospitalario

Universitario de Santiago, Hospital Clínico San Carlos, Hospital La Fe, Hospital

Universitario Puerta de Hierro Majadahonda—Instituto de Investigación Sanitaria

Puerta de Hierro—Segovia de Arana, Hospital Ramón y Cajal, IDIBGI, IdISBa, IIS

Biocruces Bizkaia, IIS Galicia Sur. Also biobanks of the Sistema de Salud de Aragón,

Sistema Sanitario Público de Andalucía, and Banco Nacional de ADN.

References

1.   Initiative, T. C.-19 H. G. & Ganna, A. A second update on mapping the human genetic
architecture of COVID-19. 2022.12.24.22283874 Preprint at
https://doi.org/10.1101/2022.12.24.22283874 (2023).

2.   GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 |
Nature. https://www.nature.com/articles/s41586-023-06034-3.

3.   Niemi, M. E. K. *et al.* Mapping the human genetic architecture of COVID-19. *Nature*
600, 472–477 (2021).

4.   Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164
(2016).

5.   Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic
Studies. *Cell* **177**, 26–31 (2019).

6.   Li, Y. R. & Keating, B. J. Trans-ethnic genome-wide association studies: advantages and
challenges of mapping in diverse populations. *Genome Med.* **6**, 91 (2014).

7.   Rosenberg, N. A. *et al.* Genome-wide association studies in diverse populations. *Nat.*
Rev. Genet. **11**, 356–366 (2010).

8.   Kwok, A. J., Mentzer, A. & Knight, J. C. Host genetics and infectious disease: new tools,
insights and translational opportunities. *Nat. Rev. Genet.* **22**, 137–153 (2021).

9.   Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious
disease in human populations. *Nat. Rev. Genet.* **15**, 379–393 (2014).

10.   Namkoong, H. *et al.* DOCK2 is involved in the host genetics and biology of severe
COVID-19. *Nature* **609**, 754–760 (2022).

11.   Bastard, P. *et al.* A loss-of-function IFNAR1 allele in Polynesia underlies severe viral
diseases in homozygotes. *J. Exp. Med.* **219**, e20220028 (2022).

12.   Duncan, C. J. A. *et al.* Life-threatening viral disease in a novel form of autosomal
recessive IFNAR2 deficiency in the Arctic. *J. Exp. Med.* **219**, e20212427 (2022).

13.   Peterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse
Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589–603
(2019).

14.   Mester, R. *et al.* Impact of cross-ancestry genetic architecture on GWAS in admixed
populations. 2023.01.20.524946 Preprint at https://doi.org/10.1101/2023.01.20.524946
(2023).

15.   Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and
to boost power | Nature Genetics. https://www.nature.com/articles/s41588-020-00766-y.

16.   Cruz, R. *et al.* Novel genes and sex differences in COVID-19 severity. *Hum. Mol. Genet.*
31, 3789–3806 (2022).

17.   Degenhardt, F. *et al.* Detailed stratified GWAS analysis for severe COVID-19 in four
European populations. *Hum. Mol. Genet.* **31**, 3945–3966 (2022).

18.   Whole-genome sequencing reveals host factors underlying critical COVID-19 | Nature.
https://www.nature.com/articles/s41586-022-04576-6.

19.   Kanai, M. *et al.* A second update on mapping the human genetic architecture of
COVID-19. *Nature* **621**, E7–E26 (2023).

20.   Evolution-based screening enables genome-wide prioritization and discovery of DNA
repair genes | PNAS. https://www.pnas.org/doi/full/10.1073/pnas.1906559116.

21.   Gioia, U. *et al.* SARS-CoV-2 infection induces DNA damage, through CHK1 degradation
and impaired 53BP1 recruitment, and cellular senescence. *Nat. Cell Biol.* **25**, 550–564 (2023).

22.   Im, J.-Y. *et al.* DDIAS promotes STAT3 activation by preventing STAT3 recruitment to
PTPRM in lung cancer cells. *Oncogenesis* **9**, 1–11 (2020).

23.   Im, J.-Y., Kang, M.-J., Kim, B.-K. & Won, M. DDIAS, DNA damage-induced apoptosis
suppressor, is a potential therapeutic target in cancer. *Exp. Mol. Med.* 1–7 (2023)
doi:10.1038/s12276-023-00974-6.

24.   Human Noxin is an anti-apoptotic protein in response to DNA damage of A549
non-small cell lung carcinoma - Won - 2014 - International Journal of Cancer - Wiley Online
Library. https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600.

25.   Angeli, F. *et al.* The spike effect of acute respiratory syndrome coronavirus 2 and
coronavirus disease 2019 vaccines on blood pressure. *Eur. J. Intern. Med.* **109**, 12–21 (2023).

26.   Silva-Aguiar, R. P. *et al.* Role of the renin-angiotensin system in the development of
severe COVID-19 in hypertensive patients. *Am. J. Physiol.-Lung Cell. Mol. Physiol.* **319**, L596–
L602 (2020).

27.   Li, Y. *et al.* The emerging role of ISWI chromatin remodeling complexes in cancer. *J.*
Exp. Clin. Cancer Res. **40**, 346 (2021).

28.   Xia, L. *et al.* lnc-BAZ2B promotes M2 macrophage activation and inflammation in
children with asthma through stabilizing BAZ2B pre-mRNA. *J. Allergy Clin. Immunol.* **147**, 921-
932.e9 (2021).

29.   The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance
Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal
Compartments | Journal of Cell Biology | Rockefeller University Press.
https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-
Dec.

30.   Sims, A. C. *et al.* Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear
Import Block Enhances Host Transcription in Human Lung Cells. *J. Virol.* **87**, 3885–3902 (2013).

31.   A Network Integration Approach to Predict Conserved Regulators Related to
Pathogenicity of Influenza and SARS-CoV Respiratory Viruses | PLOS ONE.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374.

32.   Gómez-Carballa, A. *et al.* A multi-tissue study of immune gene expression profiling
highlights the key role of the nasal epithelium in COVID-19 severity. *Environ. Res.* **210**, 112890
(2022).

33.   Policard, M., Jain, S., Rego, S. & Dakshanamurthy, S. Immune characterization and
profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-
CoV-2 oncogenesis mechanism. *Virus Res.* **301**, 198464 (2021).

34.   Wei, J. *et al.* Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2
Infection. *Cell* **184**, 76-91.e13 (2021).

35.   Wei, J. *et al.* Pharmacological disruption of mSWI/SNF complex activity restricts SARS-
CoV-2 infection. *Nat. Genet.* **55**, 471–483 (2023).

36.   Pereira, A. C. *et al.* Genetic risk factors and COVID-19 severity in Brazil: results from
BRACOVID study. *Hum. Mol. Genet.* **31**, 3021–3031 (2022).

37.   Zhu, X. *et al.* ZBTB7A promotes virus-host homeostasis during human coronavirus 229E
infection. *Cell Rep.* **41**, 111540 (2022).

38.   Gupta, S. *et al.* Emerging role of ZBTB7A as an oncogenic driver and transcriptional
repressor. *Cancer Lett.* **483**, 22–34 (2020).

39.   Yoneyama, M. *et al.* Direct triggering of the type I interferon system by virus infection:
activation of a transcription factor complex containing IRF-3 and CBP/p300. *EMBO J.* **17**, 1087–
1095 (1998).

40.   Yang, Q. *et al.* SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP-
dependent pathways. *J. Med. Virol.* **95**, e28383 (2023).

41.   Horowitz, J. E. *et al.* Genome-wide analysis provides genetic evidence that ACE2
influences COVID-19 risk and yields risk scores associated with severe disease. *Nat. Genet.* **54**,
382–392 (2022).

42.   Harris, P. A. *et al.* Research electronic data capture (REDCap)—A metadata-driven
methodology and workflow process for providing translational research informatics support. *J.*
Biomed. Inform. **42**, 377–381 (2009).

43.   Harris, P. A. *et al.* The REDCap consortium: Building an international community of
software platform partners. *J. Biomed. Inform.* **95**, 103208 (2019).

44.   Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-
Based Linkage Analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

45.   Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in
unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).

46.   Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74
(2015).

47.   Mao, X. *et al.* A Genomewide Admixture Mapping Panel for Hispanic/Latino
Populations. *Am. J. Hum. Genet.* **80**, 1171–1178 (2007).

48.   Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for
complex traits. *Nature* **570**, 514–518 (2019).

49.   Zheng, X. & Davis, J. W. SAIGEgds—an efficient statistical tool for large-scale PheWAS
with mixed models. *Bioinformatics* **37**, 728–730 (2021).

50.   Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample
relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).

51.   METAL: fast and efficient meta-analysis of genomewide association scans |
Bioinformatics | Oxford Academic.
https://academic.oup.com/bioinformatics/article/26/17/2190/198154.

52.   McGuire, D. *et al.* Model-based assessment of replicability for genome-wide
association meta-analysis. *Nat. Commun.* **12**, 1964 (2021).

53.   Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).

54.   MAGMA: Generalized Gene-Set Analysis of GWAS Data | PLOS Computational Biology.
https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219.

55.   Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait-
associated genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* **49**,
D1311–D1320 (2021).

56.   McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).

57.   Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at
GWAS loci. *Genome Biol.* **22**, 49 (2021).

58.   Barbeira, A. N. *et al.* GWAS and GTEx QTL integration. Zenodo
https://doi.org/10.5281/zenodo.3518299 (2019).

59.   Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene
expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).

60.   Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues
improves association detection. *PLOS Genet.* **15**, e1007889 (2019).

61.   Kachuri, L. *et al.* Gene expression in African Americans, Puerto Ricans and Mexican
Americans reveals ancestry-specific patterns of genetic architecture. *Nat. Genet.* **55**, 952–963
(2023).

62.   Genome-wide patterns of population structure and admixture among Hispanic/Latino
populations | PNAS. https://www.pnas.org/doi/10.1073/pnas.0914618107?url_ver=Z39.88-
2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

998   **Table 1. Demographic characteristics of the SCOURGE Latin American cohort.**

Variable	Non Hospitalized N = 1,887	Hospitalized N = 1,625
Age – mean years ± SD	39.1 ± 11.9	54.1 ±14.5
Sex - N (%)		
Female (%)	1253 (66.4)	668 (41.1)
GIA* – % mean ±SD		
European	54.4 ±16.2	39.4 ± 20.7
African	15.3 ± 12.7	9.1 ± 11.6
Native American	30.3 ± 19.8	51.3 ± 26.5
Comorbidities - N (%)		
Vascular/endocrinological	488 (25.9)	888 (64.5)
Cardiac	60 (3.2)	151 (9.3)
Nervous	15 (0.8)	61 (3.8)
Digestive	14 (0.7)	33 (2.0)
Onco-hematological	21 (1.1)	48 (3.00)
Respiratory	76 (4.0)	118 (7.3)

999   *Global genetic inferred ancestry.

1000   **Table 2. Lead independent variants in the admixed AMR GWAS meta-analysis.**

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	EAF cases	EAF controls	Nearest gene	Mamba PIP
rs13003835	2:159407982	T	C	1.20 (1.12-1.27)	3.66E-08	0.563	0.429	BAZ2B	0.30
rs35731912	3:45848457	T	C	1.65 (1.47-1.85)	6.30E-17	0.087	0.056	LZTFL1	0.95

rs2477820	6:41535254	A	T	0.84 (0.79-0.89)	1.89E-08	0.453	0.517	*FOXP4-AS1*	*0.18*
rs77599934	11:82906875	G	A	2.27 (1.7-3.04)	2.26E-08	0.016	0.011	*DDIAS*	*0.95*

1001   EA: effect allele; NEA: noneffect allele; EAF: effect allele frequency in the SCOURGE study.

1002

1003

1004

1005 **Table 3. Novel variants in the SC-HGI$_{ALL}$ and SC-HGI$_{3POP}$ meta-analyses (with**

1006 **respect to HGIv7).** Independent signals after LD clumping.

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	Nearest gene	Analysis
rs76564172	16:3892266	T	G	1.31 (1.19-1.44)	9.64E-09	*CREBBP*	SC-HGI$_{3POP}$
rs66833742	19:4063488	T	C	0.94 (0.92-0.96)	1.89E-08	*ZBTB7A*	SC-HGI$_{3POP}$
rs66833742	19:4063488	T	C	0.94 (0.92-0.96)	2.50E-08	*ZBTB7A*	SC-HGI$_{ALL}$
rs2876034	20:6492834	A	T	0.95 (0.93-0.97)	2.83E-08	*CASC20*	SC-HGI$_{ALL}$

1007 *EA: effect allele; NEA: non-effect allele.*

1008 **Figure 1. Flow chart of this study.**

1009

1010

Figure 2. A) Manhattan plot for the admixed AMR GWAS meta-analysis.

Probability thresholds at p=5x10^{-8} and p=5x10^{-5} are indicated by the horizontal lines.

Genome-wide significant associations with COVID-19 hospitalizations were found on

chromosome 2 (within *BAZ2B*), chromosome 3 (within *LZTFL1*), chromosome 6

(within *FOXP4*), and chromosome 11 (within *DDIAS*). A Quantile☐Quantile plot is

shown in supplementary Figure 2. **B) Regional association plots for rs1003835 at**

chromosome 2 and rs77599934 at chromosome 11; **C) Allele frequency distribution**

across the 1000 Genomes Project populations for the lead variants rs1003835 and

rs77599934. Retrieved from *The Geography of Genetic Variants Web* or GGV.

1020

A.

1021

B.

1022

C.

1023

1024

1025

1026

Figure 3. Forest plot showing effect sizes and the corresponding confidence intervals for the sentinel variants identified in the AMR meta-analysis across populations. All beta values with their corresponding CIs were retrieved from the B2 population-specific meta-analysis from the HGI v7 release, except for AMR, for which the beta value and IC from the HGI$_{AMR}$-SCOURGE meta-analysis are represented.

1032

1033

1034

1035 **Figure 4. (A) Polygenic risk stratified by PGS deciles comparing each risk group**

1036 **against the lowest risk group (OR-95% CI); (B) Distribution of the PGS scores in**

1037 **each of the severity scale classes** . 0-Asymptomatic, 1-Mild disease, 2-Moderate

1038 disease, 3-Severe disease, 4-Critical disease.

1039

1040

1041

1042

1043 **Figure 5. Summary of the results from gene prioritization strategies used for**

1044 **genetic associations in AMR populations.** GWAS catalog association for *BAZ2B-AS*

1045 was with FEV/FCV ratio. Literature based evidence is further explored in discussion.

1046